Clinical Trials Directory

Trials / Unknown

UnknownNCT04658992

The Registration on the Use of Feilike Heji in Minors

A Study on the Registration of the Use of Feilike Heji in Minors

Status
Unknown
Phase
Study type
Observational
Enrollment
3,000 (estimated)
Sponsor
China Academy of Chinese Medical Sciences · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

Feilike HeJi is produced by Guizhou Jianxing Pharmaceutical Co. LTD. For the treatment of phlegm heat caused by lung cough phlegm yellow, bronchial asthma, bronchitis, see the syndrome of proprietary Chinese medicine (approval number: Z20025136) approved by the state and the drug from radix scutellariae, radix peucedani, radix stemonae, red gentian root of deal, phoenix tree, spreading hedyotis herb, red tube 7 flavour, with qingrejiedu, antitussive expectorant effect. In order to fully understand the safety of Feilike HeJi in clinical practice and fulfill the responsibility of production enterprises for patients, the production enterprises initiated this study to further evaluate the safety and understanding of the function characteristics of Feilike HeJi in a wide range of people, so as to guide the clinical rational drug use.

Conditions

Timeline

Start date
2020-12-15
Primary completion
2021-12-01
Completion
2022-03-01
First posted
2020-12-09
Last updated
2021-08-04

Locations

21 sites across 1 country: China

Source: ClinicalTrials.gov record NCT04658992. Inclusion in this directory is not an endorsement.